



<b>External assessment centre (EAC) representatives present:</b>	<ul style="list-style-type: none"> <li>· Dr Susan O'Connell, Senior Researcher, Cedar</li> <li>· Dr Megan Dale, Researcher, Cedar</li> </ul>	<ul style="list-style-type: none"> <li>· Present for items 1-8 &amp; 10-14</li> <li>· Present for items 1-8 &amp; 10-14</li> </ul>
<b>Expert advisers present</b>	<ul style="list-style-type: none"> <li>· Dr Allison Farnworth, Senior Research Midwife, Institute of Cellular Medicine at Newcastle University</li> <li>· Dr Paul Ayuk, Consultant Obstetrician, Newcastle-upon-Tyne Hospitals NHS Trust</li> <li>· Dr Latha Vinayakarao, Consultant Obstetrician, Poole Hospital NHS Foundation Trust</li> <li>· Dr Patricia Seddon, Locum Consultant Obstetrician, St. Mary's Hospital, Manchester University NHS Foundation Trust</li> <li>· Dr Ben Wakerley, Neurology Consultant, Gloucester Royal Hospital, Gloucestershire Hospital NHS Foundation Trust</li> <li>· Dr Brendan Davies, Consultant Neurologist, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust</li> </ul>	<ul style="list-style-type: none"> <li>· Present for items 1-8</li> <li>· Present for items 1-8</li> <li>· Present for items 1-8</li> <li>· Present for items 1-8</li> <li>· Present for items 10-14</li> <li>· Present for items 10-14</li> </ul>
<b>Non-public present:</b>	<ul style="list-style-type: none"> <li>· Ian Mather, Business Analyst, Resource Impact Assessment Team, NICE</li> <li>· Emilene Coventry, Senior Medical Editor, Publishing Team, NICE</li> </ul>	<ul style="list-style-type: none"> <li>· Present for items 1-16</li> <li>· Present for items 1-16</li> </ul>

### **Introduction to the meeting**

1. The chair welcomed all members of the committee and other attendees present to the meeting.

### **News and announcements**

2. The chair offered news and announcements and noted committee members who had given apologies for the meeting.

### **Minutes of previous meeting**

3. The committee agreed the minutes from the 14<sup>th</sup> June 2019 committee meeting.

## **MT457 Episcissors-60 for guided mediolateral episiotomy**

### **Part 1 – Open session**

4. The chair welcomed the invited experts, external assessment centre representatives, members of the public and company representatives from Medinvent. The chair then explained the code of conduct to the members of the public observing the meeting.
5. The chair asked all committee members, experts, NICE staff and observers to declare any relevant interests in relation to the technology being considered.
  - Dr Allison Farnworth declared a direct non-financial professional interest ahead of the meeting as she is a co-author on a published paper: “Obstetric anal sphincter injuries (OASIs) before and after the introduction of the Episcissors-60: A multi-centre time series analysis” with Dr Paul Ayuk and Prof Stephen Robson. Dr Farnworth also had time funded by Academic Health Science Network North East and North Cumbria to complete a project exploring implementation of Episcissors-60 in the region (0.2WTE for 12 months).
    - It was agreed that her declarations would not prevent Dr Farnworth from providing expert advice to the committee.
  - Dr Paul Ayuk declared a direct non-financial professional interest ahead of the meeting as he is a lead author of the paper: ‘Obstetric anal sphincter injuries (OASIs) before and after the introduction of the Episcissors-60: A multi-centre time series analysis.’ Revised version submitted for publication. Dr Ayuk is also at early stages of a proposal for a randomised controlled trial to evaluate the Episcissors-60.
    - It was agreed that his declarations would not prevent Dr Ayuk from providing expert advice to the committee.

No other interests were declared.

6. The committee was asked if there were any specific equality issues to consider in relation to the technology being considered.
7. The topic was introduced by Mr Abdullah Pandor and Prof Shaheen Hamdy with Dr Allison Farnworth, Dr Paul Ayuk, Dr Latha Vinayakarao and Dr Patricia Seddon providing expert advice.
8. The chair thanked the experts, external assessment centre representatives, members of the public and company representatives for their attendance and they left the meeting.

## **Part 2 – Closed session**

9. The committee then proposed draft recommendations on the technology and these recommendations were reached by consensus.

### **MT323 gammaCore for cluster headache**

## **Part 1 – Open session**

10. The chair welcomed the invited experts, external assessment centre representatives, members of the public and company representatives from electroCore. The chair then explained the code of conduct to the members of the public observing the meeting.
11. The chair asked all committee members, experts, NICE staff and observers to declare any relevant interests in relation to the technology being considered.

- Dr Brendan Davies declared a non-financial professional interest ahead of the meeting as he is a co-author on a published paper in the journal of Headache and Pain on the real-world use of the gammaCore device for the treatment of 30 patients with cluster headache in the UK. The paper was published in November 2018.

Dr Brendan Davies also declared an indirect interest as well ahead of the meeting as he is currently acting as a UK principal investigator in commercial study of Galcanezumab, an anti-CGRP monoclonal antibody vs. placebo as a potential treatment for cluster headache.

- It was agreed that his declarations would not prevent Dr Davies from providing expert advice to the committee.
- Dr Benjamin Wakerley declared an indirect interest ahead of the meeting as he runs the Oxford headache symposium, an annual non-profit making headache meeting that has been hosted in Oxford. Dr Wakerley has organised the meeting since 2016 and it is attended by neurologists, GPs and nurses with specialist interest in headache. Typically, the event is sponsored by other pharmaceutical companies related to headache – e.g. Allergan, Novartis, Cefaly.
- It was agreed that his declarations would not prevent Dr Wakerley from providing expert advice to the committee.

No other interests were declared.

12. The committee was asked if there were any specific equality issues to consider in relation to the technology being considered.
13. The topic was introduced by Dr Teik Goh, with Dr Ben Wakerley and Dr Brendan Davies providing expert advice.

14. The chair thanked the experts, external assessment centre representatives, members of the public and company representatives for their attendance and they left the meeting.

**Part 2 – Closed session**

15. The committee then proposed final recommendations on the technology and these recommendations were reached by consensus.

**Date of the next meeting**

16. The next meeting of the medical technologies advisory committee will be held on Friday 18 October 2019 and will start promptly at 10:00am. The meeting will be held at the NICE Manchester offices, Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BT.